2023 World Conference on Lung Cancer (Posters)-P1.22. Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study

P1.22. Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the accuracy of two different platforms, next-generation sequencing (NGS) and Fluorescence in Situ Hybridization (FISH), in detecting MET amplification in Chinese lung cancer patients. MET amplification detection is important in understanding resistance to EGFR-Tyrosine kinase inhibitors (TKIs). The study also sought to evaluate the sensitivity of MET amplification detection in circulating tumor DNA (ctDNA) using NGS. <br /><br />The researchers enrolled 67 patients who were resistant to EGFR-TKI therapies and performed tissue biopsies for both NGS and FISH testing to detect MET amplification. Plasma samples were also collected for ctDNA analysis. The results showed that MET amplification was detected in 32.8% of patients, with 36.4% showing polysomy and 63.6% showing focal amplification by FISH. The detection rate of MET amplification in patients resistant to third-generation TKIs was significantly higher than those resistant to 1st- and 2nd-generation TKIs.<br /><br />The study found that tissue NGS and FISH had an overall agreement of 83.6% in detecting MET amplification. Tissue NGS demonstrated a sensitivity of 85.7% and a specificity of 91.3% compared to FISH. For focal MET amplification, NGS achieved a sensitivity of 78.6%, a specificity of 100%, and an agreement of 94.6%. For polysomy, NGS had a sensitivity of 42.9%, a specificity of 91.3%, and an agreement of 84.9%. <br /><br />In detecting MET amplification in ctDNA using NGS, the sensitivity was 14.3% and the specificity was 100% compared to FISH. <br /><br />In conclusion, tissue NGS showed good concordance with FISH in detecting MET amplification in lung cancer patients resistant to EGFR-TKI therapies. However, the sensitivity of ctDNA NGS in detecting MET amplification needs further improvement.

Asset Subtitle

Xue Lin

Meta Tag

Speaker Xue Lin

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

next-generation sequencing

Fluorescence in Situ Hybridization

MET amplification

Chinese lung cancer patients

EGFR-Tyrosine kinase inhibitors

circulating tumor DNA

tissue biopsies

third-generation TKIs

tissue NGS

ctDNA analysis